Clorox’s Q4 Hauls: Margin Pressure Persists as GOJO Integration Rolls In

Overview: a post-acquisition year of integration under a tightening margin net

The Clorox Company (NYSE: CLX) released results for the fourth quarter and fiscal year 2026 that reflect a company balancing a newly expanded portfolio with the friction of a recent ERP overhaul and a large acquisition. In late April 2026, Clorox completed the GOJO Industries purchase, now operating as Clorox Purell and bringing the Purell brand and a broader health-and-hygiene solutions footprint into the fold. Management framed this year as one of disciplined execution despite ongoing consumer and macro headwinds, with a clear emphasis on integrating the GOJO assets while continuing to modernize systems.

Key Q4 FY26 numbers at a glance

• Net sales for the fourth quarter declined 2% to about $1.95 billion. The GOJO acquisition contributed roughly 10 percentage points to that topline, with organic sales down about 13%.
• The gross margin contracted by 520 basis points, ending at 41.3% versus 46.5% a year earlier. Deterioration was driven by lower volumes, the inventory step-up tied to the GOJO deal, higher commodity costs, and greater manufacturing and logistics costs. Management notes that ERP-related shipment comparisons and the GOJO inventory step-up each shaved roughly 150 basis points from gross margin.
• Diluted EPS fell 50% to $1.34 in the quarter, while adjusted EPS dropped 42% to $1.66. The year-ago quarter benefited from a lighter cost base and, in part, from the non-GAAP framing of earnings that management highlights as a factor in comparing apples-to-apples bases year over year.
• The company reiterates that the press release contains Non-GAAP financial information and footnotes explaining the Organic sales growth/decrease and adjusted EPS as reconciliations to GAAP figures.

The quarter’s narrative is that the GOJO add-on and ERP transition created a large-numbers backdrop: the revenue lift from the acquisition was offset by ERP and integration costs, inventory step-ups, and cost volatility. In other words, the arithmetic of “more revenue, less margin” remained in fashion for Clorox in Q4.

GOJO integration: what changed and what didn't

The GOJO acquisition, completed in April 2026, expands Clorox’s portfolio and adds the Purell brand and related health-and-hygiene solutions. Management emphasized that the integration is foundational but still ramping, with ERP implementations and process modernization described as critical milestones for long-run efficiency and scalability. The company attributes a portion of the gross margin pressure to the inventory step-up required by the acquisition, and to ERP-related shipment comparisons that altered quarterly comparables.

Even with these headwinds, leadership framed the GOJO move as strategically valuable, expanding the growth runway and stabilizing Clorox’s consumer-health corridor. The question for investors is whether the mix shift toward health-and-hygiene and the enhanced distribution through GOJO’s portfolio can translate into higher-margin opportunities over the medium term, once ERP-related distortion abates and GOJO synergies mature.

Outlook and implications for FY27

Looking ahead, Clorox executives cautioned that the operating environment is expected to stay challenging, with ongoing cost volatility and a consumer base that remains value-focused. Yet the leadership remains constructive about the company’s strategic trajectory. They describe the year as one where the combination of GOJO’s expanded portfolio, U.S. ERP modernization, and continued investment in brands and digital capabilities should position Clorox to re-accelerate organic growth once the near-term headwinds subside.

Analytically, this translates into a cautious revenue forecast environment, with no aggressive near-term top-line targets but a focus on building a stronger operating foundation. Management’s confidence rests on their ability to reduce friction from ERP and integration costs over time, coupled with an improving go-to-market and innovation pipeline. The press release emphasizes that the actions taken—portfolio expansion, ERP modernization, and productivity enhancements—are designed to create a durable base for future EPS growth, even if the current year is defined by margin compression and high integration costs.

What this could portend for peers and the sector

The Clorox narrative—acquisition-driven top-line shifts, ERP-related margin drag, and an eye toward cost discipline—reads like a familiar playbook for consumer-packaged goods in a period of accelerated consolidation and portfolio repositioning. For peers, the message is twofold: manage integration costs and inventory step-ups with rigorous discipline, and invest in brands and channels that can withstand macro shocks while delivering long-term price/mix benefits.

In markets where the balance sheet can accommodate large acquisitions, the short-term margin hit may be offset by future scale and portfolio resilience. The adoption of enhanced data capabilities and digital investments could become a differentiator if they yield faster response times to consumer demand, more effective trade spend optimization, and stronger price realization—factors that could influence EPS consensus trends in the quarters ahead.

Non-GAAP disclosures and what investors should watch

As with many corporate disclosures tied to big deals, Clorox stresses Non-GAAP metrics to illustrate ongoing operating performance separate from one-time integration costs and transaction-related effects. Investors should watch how the reconciliation to GAAP evolves over subsequent quarters as ERP upgrades stabilize and GOJO-related synergies begin to accrue. The EPS line, especially the gap between GAAP and adjusted figures, will be a focal point for EPS consensus revisions if the company sustains margin headwinds for longer than anticipated.

Bottom line: a strategic repositioning with a lumpy near term

Clorox’s FY26 narrative is less about a single quarter’s magic and more about how the GOJO bolt joins a broader transformation. The marked EPS decline reflects a combination of top-line pressure and the cost of modernization, not a failure of the core brand portfolio. The company’s framing—entering FY27 with a strengthened portfolio, a modernized operational backbone, and a plan to deliver long-term value—reads as a deliberate bet on resilience through reinvestment. If the non-GAAP adjustments begin to align with improving gross margins and stabilizing volumes, the earnings surprise dynamic could shift in the coming year, potentially re-centering expectations around the revenue forecast and long-run EPS trajectory for CLX and comparable peers.

For now, the quarter’s numbers are a reminder that acquisitions can stretch margins before they strengthen a company’s growth profile. The question for investors and sector peers is whether the GOJO synergy and ERP modernization deliver the lift promised, or whether the near-term headwinds become a longer chapter in Clorox’s earnings narrative.